Author Tanimoto, Ryuta| Sakaguchi, Masakiyo| Abarzua, Fernando| Kataoka, Ken| Kurose, Kaoru| Murata, Hitoshi| Nasu, Yasutomo| Kumon, Hiromi| Huh, Nam-Ho|
Published Date 2010-04-01
Publication Title International Journal of Cancer
Volume volume126
Issue issue7
Content Type Journal Article
Author Sakaguchi, Masakiyo| Kataoka, Ken| Abarzua, Fernando| Tanimoto, Ryuta| Watanabe, Masami| Murata, Hitoshi| Than, Swe Swe| Kurose, Kaoru| Kashiwakura, Yuji| Ochiai, Kazuhiko| Nasu, Yasutomo| Kumon, Hiromi| Huh, Nam-ho|
Published Date 2009-05-22
Publication Title The Journal of Biological Chemistry
Volume volume284
Issue issue21
Content Type Journal Article
JaLCDOI 10.18926/AMO/32868
FullText URL fulltext.pdf
Author Arata, Ryoji| Saika, Takashi| Tsushima, Tomoyasu| Abarzua, Fernando| Nasu, Yasutomo| Kumon, Hiromi|
Abstract To compare the quality of life (QOL) in patients with ileal neobladder and sigmoidal neobladder, a retrospective survey was conducted using a formulated questionnaire. Between January and March 1999, a QOL survey was conducted using self-administered questionnaires (EORTC QLQ-C30, IPSS, supplemented with detailed questionnaires about continence, sexual function, and patient’s satisfaction with the selected urinary diversion method) for 78 patients with orthotopic urinary reservoir (OUR) who were followed-up for more than 3 months after cystectomy. Among 78 patients, 63 had OUR using an ileal segment (male/female=59/4, median age: 70.8 years old, median follow-up: 1.7 years). Fifteen patients had OUR using a sigmoidal segment (male/female=13/2, median age: 71.9, median follow-up: 3.9). The QLQ-C30 functional evaluation and the items in relation to sexual function showed no diff erences between the 2 groups. Concerning the voiding condition, bladder emptying, frequency, and urgency, scores in the sigmoidal OUR group were signifi cantly higher. The QOL score concerning voiding conditions, daytime, and nighttime continence and quantity of pad showed a better score in the ileal OUR group. Concerning the satisfaction with methods of urinary diversion, patients in the sigmoidal OUR group expressed less satisfaction than their preoperative expectations. Considering several postoperative voiding conditions, ileal OUR seems superior to sigmoidal OUR.
Keywords urinary diversion orthotopic urinary reservoirs bladder cancer quality of life
Amo Type Original Article
Published Date 2007-08
Publication Title Acta Medica Okayama
Volume volume61
Issue issue4
Publisher Okayama University Medical School
Start Page 229
End Page 234
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 17726512
Web of Sience KeyUT 000248957100007
JaLCDOI 10.18926/AMO/32084
FullText URL fulltext.pdf
Author Abarzua, Fernando| Monden, Koichi| Nagai, Atsushi| Nasu, Yasutomo| Kumon, Hiromi|
Abstract <p>Ureteroscopy has evolved in many aspects, particularly in the flexibility and size of ureteroscopes. We have developed a new detachable access sheath to make ureteroscopic procedures more straight-forward and to reduce possible damage to delicate instruments used in the procedure.</p>
Keywords ureteroscopy detachable accesss heath
Amo Type Article
Published Date 2004-08
Publication Title Acta Medica Okayama
Volume volume58
Issue issue4
Publisher Okayama University Medical School
Start Page 215
End Page 216
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 15551759
Web of Sience KeyUT 000223559700006
JaLCDOI 10.18926/AMO/31973
FullText URL fulltext.pdf
Author Edamura, Kohei| Saika, Takashi| Senoh, Takashi| Koizumi, Fumihito| Manabe, Daisuke| Ebara, Shin| Kaku, Haruki| Yokoyama, Teruhiko| Abarzua, Fernando| Nagai, Atsushi| Nasu, Yasutomo| Tsushima, Tomoyasu| Kumon, Hiromi|
Abstract <p>This study was undertaken to reveal the trends of prostate cancer and the outcome of treatment modalities for each disease stage in patients in a single institute over a 10-year period. From January 1994 through December 2003, 420 consecutive patients with previously untreated and histologically confirmed prostate cancer were analyzed for annual distributions of disease stages and treatment modalities and for long-term clinical progression-free survival, prostate cancer-specific survival, and prostate-specific antigen (PSA) failure-free survival rates for each stage and treatment modality. Annual trends showed that the number of patients, especially those with clinically localized cancer, increased dramatically. The 5-year disease-specific survival rates for patients with clinically localized disease were 100 percent for all treatment modalities, including hormonal therapy alone. Patients with PSA levels less than 10 ng/ml showed an 81 percent 5-year PSA failure-free survival rate with radical prostatectomy. Stage C patients treated by surgery or radiation-based therapy with concomitant hormonal therapy obtained 93 percent and 100 percent cause-specific survival rates, respectively, and those treated by hormonal therapy alone showed a 79 percent rate. The number of patients with localized prostate cancer was increasing in this decade. While long-term hormonal therapy alone was highly efficient in controlling localized prostate cancer, radical therapies in conjunction with neo-adjuvant hormonal therapy produced better survival rates in cases of locally advanced disease.</p>
Keywords prostate carcinoma long-term cohort retrospective outcome
Amo Type Article
Published Date 2005-10
Publication Title Acta Medica Okayama
Volume volume59
Issue issue5
Publisher Okayama University Medical School
Start Page 195
End Page 199
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 16286958
Web of Sience KeyUT 000232835600003
JaLCDOI 10.18926/AMO/30945
FullText URL fulltext.pdf
Author Kobayashi, Tomoko| Sakaguchi, Masakiyo| Tanimoto, Ryuta| Abarzua, Fernando| Takaishi, Mikiro| Kaku, Haruki| Kataoka, Ken| Saika, Takashi| Nasu, Yasutomo| Miyazaki, Masahiro| Kumon, Hiromi| Huh, Nam-ho|
Abstract <p>We have recently shown that a new therapeutic modality using the REIC/Dkk-3 gene (Ad-REIC) is effective against various human cancers, including those of prostate, testis and breast origins. The aim of the present study was to examine the sensitivity of bladder cancers to Ad-REIC and to clarify the molecular mechanisms that determine sensitivity/resistance. We found that 2 human bladder cancer cell lines, T24 and J82, are resistant to Ad-REIC. In T24 and J82 cells, the ER stress response and activation of JNK were observed in a manner similar to that in the sensitive PC3 cells. Translocation of Bax to mitochondria occurred in PC3 cells but not in T24 and J82 cells. Bcl-2 was remarkably overexpressed in T24 and J82 compared with the expression levels in sensitive cell lines. Treatment of T24 and J82 cells with a Bcl-2 inhibitor sensitized the cells to Ad-REIC-induced apoptosis. The results indicate that some human bladder cancers are resistant to apoptosis induced by overexpression of REIC/Dkk-3, which is at least in part due to up-regulation of Bcl-2. These results provide a basis for possible use of Bcl-2 as a marker of sensitive cancers and to try to sensitize resistant cancers to Ad-REIC by down-regulation of Bcl-2.</p>
Keywords REIC/Dkk-3 bladder cancer apoptosis Bcl-2
Amo Type Original Article
Published Date 2008-12
Publication Title Acta Medica Okayama
Volume volume62
Issue issue6
Publisher Okayama University Medical School
Start Page 393
End Page 401
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
Web of Sience KeyUT 000262025000006
JaLCDOI 10.18926/AMO/30759
FullText URL fulltext.pdf
Author Kaku, Haruki| Saika, Takashi| Tsushima, Tomoyasu| Nagai, Atsushi| Yokoyama, Teruhiko| Abarzua, Fernando| Ebara, Shin| Manabe, Daisuke| Nasu, Yasutomo| Kumon, Hiromi|
Abstract <p>We evaluated the efficiency and toxicity of estramustine phosphate (ECT), ifosfamide (IFM) and cisplatin (CDDP) combination chemotherapy in twenty-one patients with hormone-refractory prostate cancer (HRPC), for which there is currently no effective treatment. Patients received a daily dose of 560 mg ECT in combination with 1.2 g/m2 IFM on days 1 to 5 and 70 mg/m2 CDDP on day 1. This combination therapy was given every 3 to 4 weeks. An objective response of more than 50% reduction in prostate-specific antigen was observed in 9 of 18 patients (50%), and a more than 50% reduction in bi-dimensionally measurable soft-tissue lesions was observed in 2 of 7 patients (29%). The median duration of response among the cases showing partial response was 40 weeks, while the median duration of response of overall partial-response plus stable cases was 30 weeks. The median survival duration of all cases was 47 weeks. Toxicity was modest and acceptable. In conclusion, the ECT, IFM and CDDP combination chemotherapy regimen is a viable treatment option for HRPC. However, in comparison with our previous chemotherapy regimen of IFM and CDDP, no additional long-lasting effects resulting from the inclusion of ECT could be affirmed.</p>
Keywords hormone-refractory prostate cancer chemotherapy estramustine phosphate ifosfamide cisplatin
Amo Type Article
Published Date 2006-02
Publication Title Acta Medica Okayama
Volume volume60
Issue issue1
Publisher Okayama University Medical School
Start Page 43
End Page 49
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 16508688
Web of Sience KeyUT 000235538900005